Bio-Rad Laboratories, Inc. (FRA:BUWA)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.83B +30.6% |
| Revenue (ttm) | 2.27B +1.4% |
| Net Income | 194.67M -30.3% |
| EPS | 7.23 -28.2% |
| Shares Out | n/a |
| PE Ratio | 45.38 |
| Forward PE | 37.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 332.20 |
| Previous Close | 333.00 |
| Day's Range | 323.80 - 333.00 |
| 52-Week Range | 204.60 - 333.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory e... [Read more]
News
Bio-Rad price target raised to $390 from $370 at RBC Capital
RBC Capital raised the firm’s price target on Bio-Rad (BIO) to $390 from $370 and keeps an Outperform rating on the shares.
Bio-Rad price target raised to $370 from $320 at RBC Capital
RBC Capital raised the firm’s price target on Bio-Rad (BIO) to $370 from $320 and keeps an Outperform rating on the shares. Bio-Rad’s Q2 results and restructuring plans support expectations…
Bio-Rad price target raised to $330 from $300 at Citi
Citi raised the firm’s price target on Bio-Rad (BIO) to $330 from $300 and keeps a Neutral rating on the shares.
Bio-Rad Laboratories Earnings Call Transcript: Q2 2026
Q2 2026 revenue was flat year-over-year but up 10% sequentially, with clinical diagnostics returning to growth and digital PCR showing strong instrument sales. The company reaffirmed full-year guidance, announced a restructuring for long-term savings, and continues to face headwinds in China and academic markets.
Bio-Rad Laboratories Earnings release: Q2 2026
Bio-Rad Laboratories released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bio-Rad Laboratories Quarterly report: Q2 2026
Bio-Rad Laboratories has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bio-Rad Laboratories Slides: Q2 2026
Bio-Rad Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Bio-Rad inititates restructuring plan, to cut jobs
According to a regulatory filing, on July 31, 2026, Bio-Rad (BIO) Laboratories initiated a strategy-driven restructuring plan as part of our ongoing program to improve operating performance and streng...
Bio-Rad reports Q2 adjusted EPS $2.62, consensus $1.75
Reports Q2 revenue $651M, consenesus $623.99M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in C...
Bio-Rad Reports Second-Quarter 2026 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad slips as Sartorius weighed on by Danaher bioprocessing unit miss
Sartorius (SSSGY) shares are trading lower in Europe after earnings from competitor Danaher (DHR), including bioprocessing unit results that missed expectations. Bio-Rad Laboratories (BIO), which owns...
BIO-key's Fireside Chat at Maxim Group Defense Tech Conf. to Webcast Thur.
Biometric authentication provider BIO-key's (BKYI) CEO will participate in a webcast fireside chat at Maxim Group's Defense Tech Conf. 6-25 at 4pm, track 2
Bio-Rad Laboratories Transcript: Jefferies Global Healthcare Conference 2026
Leadership is driving operational transformation, focusing on R&D productivity, targeted M&A, and regional growth. Digital PCR and Quality Controls are key growth drivers, while market softness and policy changes in the US, Europe, and China remain challenges.
Bio-Rad price target raised to $310 from $290 at Wells Fargo
Wells Fargo raised the firm’s price target on Bio-Rad (BIO) to $310 from $290 and keeps an Equal Weight rating on the shares after meeting with management. The macro environment…
Bio-Rad Laboratories Transcript: RBC Capital Markets Global Healthcare Conference 2026
Digital PCR instruments saw 24% growth, led by the QX700 series, and quality controls remain a global growth focus with attractive margins. Regional challenges in the Middle East and softness in early-stage biopharma are offset by stable China operations and new local manufacturing. Margin expansion and operational efficiencies are key near-term priorities.
Activist Elliott Takes Major Stake in Bio-Rad — Can It Boost BIO Stock Price?
Activist investor Elliott Investment Management has reportedly built a sizable stake in Bio-Rad Laboratories ($BIO). According to the Wall Street Journal, Elliott is aiming to push management to impro...
Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports
Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories , and plans to push the company to boost its underperforming stock price,...
Activist investor Elliot builds big stake in Bio-Rad, WSJ says
Activist investor Elliot Investment Management has built a big stake in Bio-Rad (BIO)e Laboratories, with plans to push the company to boost its underperforming stock price, Lauren Thomas of The…
Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
Bio-Rad resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Bio-Rad (BIO) with an Outperform rating and $320 price target The company’s sales growth should recover in 2027 following “idiosyncratic product headwinds” in 2026, the...
Bio-Rad to Participate in Upcoming Investor Conferences
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will p...
Bio-Rad price target lowered to $290 from $320 at Wells Fargo
Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $290 from $320 and keeps an Equal Weight rating on the shares. The firm notes Q1 missed on organic…